Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.

Jeffrey L. Seeburger, Frederick R. Taylor, Deborah Friedman, Lawrence Newman, Yang Ge, Ying Zhang, Carolyn M. Hustad, Jeanne Lasorda, Xiaoyin Fan, David Hewitt, Tony Ho, Kathryn M. Connor

Research output: Contribution to journalArticle

Abstract

The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100mg non-responders will respond to other triptans. This was a randomized, placebo-controlled, double-blind study in adults with >1-year history of ICHD-II (International Classification of Headache Disorders, second edition) migraine who reported that they generally do not respond to sumatriptan (≥50% unsatisfactory response). In the baseline phase, participants treated a single moderate/severe migraine attack with open-label generic sumatriptan 100mg. Those who continued to experience moderate/severe pain at two hours post-dose were eligible to enter the double-blind treatment phase, during which participants treated three migraine attacks in crossover fashion (two with rizatriptan 10-mg ODT, one with placebo) after being randomly assigned to one of three treatment sequences (1:1:1 ratio). The primary endpoint was two-hour pain relief. A total of 102 (94%) participants treated at least one study migraine. Pain relief at two hours was significantly greater with rizatriptan compared with placebo (51% vs. 20%, p

Original languageEnglish (US)
Pages (from-to)786-796
Number of pages11
JournalCephalalgia
Volume31
Issue number7
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Sumatriptan
Migraine Disorders
Placebos
Pain
Tablets
Tryptamines
Therapeutics
Headache Disorders
Double-Blind Method
rizatriptan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Seeburger, J. L., Taylor, F. R., Friedman, D., Newman, L., Ge, Y., Zhang, Y., ... Connor, K. M. (2011). Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia, 31(7), 786-796. https://doi.org/10.1177/0333102410390399

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. / Seeburger, Jeffrey L.; Taylor, Frederick R.; Friedman, Deborah; Newman, Lawrence; Ge, Yang; Zhang, Ying; Hustad, Carolyn M.; Lasorda, Jeanne; Fan, Xiaoyin; Hewitt, David; Ho, Tony; Connor, Kathryn M.

In: Cephalalgia, Vol. 31, No. 7, 05.2011, p. 786-796.

Research output: Contribution to journalArticle

Seeburger, JL, Taylor, FR, Friedman, D, Newman, L, Ge, Y, Zhang, Y, Hustad, CM, Lasorda, J, Fan, X, Hewitt, D, Ho, T & Connor, KM 2011, 'Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.', Cephalalgia, vol. 31, no. 7, pp. 786-796. https://doi.org/10.1177/0333102410390399
Seeburger, Jeffrey L. ; Taylor, Frederick R. ; Friedman, Deborah ; Newman, Lawrence ; Ge, Yang ; Zhang, Ying ; Hustad, Carolyn M. ; Lasorda, Jeanne ; Fan, Xiaoyin ; Hewitt, David ; Ho, Tony ; Connor, Kathryn M. / Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. In: Cephalalgia. 2011 ; Vol. 31, No. 7. pp. 786-796.
@article{bb055ff2371e466ab63990de1031e982,
title = "Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.",
abstract = "The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100mg non-responders will respond to other triptans. This was a randomized, placebo-controlled, double-blind study in adults with >1-year history of ICHD-II (International Classification of Headache Disorders, second edition) migraine who reported that they generally do not respond to sumatriptan (≥50{\%} unsatisfactory response). In the baseline phase, participants treated a single moderate/severe migraine attack with open-label generic sumatriptan 100mg. Those who continued to experience moderate/severe pain at two hours post-dose were eligible to enter the double-blind treatment phase, during which participants treated three migraine attacks in crossover fashion (two with rizatriptan 10-mg ODT, one with placebo) after being randomly assigned to one of three treatment sequences (1:1:1 ratio). The primary endpoint was two-hour pain relief. A total of 102 (94{\%}) participants treated at least one study migraine. Pain relief at two hours was significantly greater with rizatriptan compared with placebo (51{\%} vs. 20{\%}, p",
author = "Seeburger, {Jeffrey L.} and Taylor, {Frederick R.} and Deborah Friedman and Lawrence Newman and Yang Ge and Ying Zhang and Hustad, {Carolyn M.} and Jeanne Lasorda and Xiaoyin Fan and David Hewitt and Tony Ho and Connor, {Kathryn M.}",
year = "2011",
month = "5",
doi = "10.1177/0333102410390399",
language = "English (US)",
volume = "31",
pages = "786--796",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.

AU - Seeburger, Jeffrey L.

AU - Taylor, Frederick R.

AU - Friedman, Deborah

AU - Newman, Lawrence

AU - Ge, Yang

AU - Zhang, Ying

AU - Hustad, Carolyn M.

AU - Lasorda, Jeanne

AU - Fan, Xiaoyin

AU - Hewitt, David

AU - Ho, Tony

AU - Connor, Kathryn M.

PY - 2011/5

Y1 - 2011/5

N2 - The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100mg non-responders will respond to other triptans. This was a randomized, placebo-controlled, double-blind study in adults with >1-year history of ICHD-II (International Classification of Headache Disorders, second edition) migraine who reported that they generally do not respond to sumatriptan (≥50% unsatisfactory response). In the baseline phase, participants treated a single moderate/severe migraine attack with open-label generic sumatriptan 100mg. Those who continued to experience moderate/severe pain at two hours post-dose were eligible to enter the double-blind treatment phase, during which participants treated three migraine attacks in crossover fashion (two with rizatriptan 10-mg ODT, one with placebo) after being randomly assigned to one of three treatment sequences (1:1:1 ratio). The primary endpoint was two-hour pain relief. A total of 102 (94%) participants treated at least one study migraine. Pain relief at two hours was significantly greater with rizatriptan compared with placebo (51% vs. 20%, p

AB - The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100mg non-responders will respond to other triptans. This was a randomized, placebo-controlled, double-blind study in adults with >1-year history of ICHD-II (International Classification of Headache Disorders, second edition) migraine who reported that they generally do not respond to sumatriptan (≥50% unsatisfactory response). In the baseline phase, participants treated a single moderate/severe migraine attack with open-label generic sumatriptan 100mg. Those who continued to experience moderate/severe pain at two hours post-dose were eligible to enter the double-blind treatment phase, during which participants treated three migraine attacks in crossover fashion (two with rizatriptan 10-mg ODT, one with placebo) after being randomly assigned to one of three treatment sequences (1:1:1 ratio). The primary endpoint was two-hour pain relief. A total of 102 (94%) participants treated at least one study migraine. Pain relief at two hours was significantly greater with rizatriptan compared with placebo (51% vs. 20%, p

UR - http://www.scopus.com/inward/record.url?scp=80054098209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054098209&partnerID=8YFLogxK

U2 - 10.1177/0333102410390399

DO - 10.1177/0333102410390399

M3 - Article

C2 - 21078681

AN - SCOPUS:80054098209

VL - 31

SP - 786

EP - 796

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -